EUVIMEDEUVIMED entdecken
Crossref

METTL5: A Potential Biomarker for Nonsmall Cell Lung Cancer That Promotes Cancer Cell Proliferation by Interacting with IGF2BP3

Sihan Gong iD, Hu Liu, Hao Gou, Wanli Sun

Genetic Testing and Molecular Biomarkers · 2024

DOI: 10.1089/gtmb.2023.0531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetic Testing and Molecular Biomarkers, 2024. Verfasst von Sihan Gong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, People's Hospital of Tongjiang County, Bazhong City, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Cell Proliferation, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine if METTL5 promotes the proliferation of nonsmall cell lung cancer (NSCLC) cells by interacting with IGF2BP3.

Methods

The expression patterns of METTL5 and IGF2BP3 in NSCLC tissues, their relationship with survival rate, and their correlation were analyzed using bioinformatics and clinical sample analyses. The effects of METTL5 overexpression and IGF2BP3 knockdown, as well as those of METTL5 knockdown and IGF2BP3 overexpression, on the proliferation of NSCLC cells were analyzed by transfecting appropriate constructs. The interaction between METTL5 and IGF2BP3 was verified using the co-immunoprecipitation (Co-IP) assay. The in vivo effects of METTL5 and IGF2BP3 on NSCLC growth were analyzed using the tumor-bearing nude mouse model.

Results

METTL5 and IGF2BP3 expression levels were positively correlated and were associated with poor clinical prognosis. The METTL5 and IGF2BP3 expression levels were upregulated in the clinical NSCLC samples. IGF2BP3 expression did not affect METTL5 expression but was regulated by METTL5. IGF2BP3 overexpression mitigated the METTL5 knockdown-induced impaired cell proliferation. Meanwhile, IGF2BP3 knockdown suppressed METTL5-mediated NSCLC cell proliferation. The Co-IP assay results revealed the interaction between METTL5 and IGF2BP3 in NSCLC cells. IGF2BP3 knockdown suppressed tumor growth, whereas IGF2BP3 overexpression enhanced tumor volume and quality.

Conclusion

METTL5 induces NSCLC cell proliferation by interacting with IGF2BP3. Thus, METTL5 is a potential biomarker and a therapeutic target for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungCell ProliferationGene Expression Regulation, NeoplasticLung NeoplasmsMethyltransferasesMice, NudeRNA-Binding ProteinsAnimalsFemaleHumansMaleMiceMiddle AgedCell Line, TumorPrognosis

Stichwörter der Autor:innen

IGF2BP3METTL5biomarkernonsmall cell lung cancerproliferation

Substanzen

Biomarkers, TumorIGF2BP3 protein, humanMethyltransferasesRNA-Binding ProteinsMETTL5 protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, People's Hospital of Tongjiang County, Bazhong City, China.

ORCID-Profile: Sihan Gong

Zitieren

APA

Gong, S., Liu, H., Gou, H., & Sun, W. (2024). METTL5: A Potential Biomarker for Nonsmall Cell Lung Cancer That Promotes Cancer Cell Proliferation by Interacting with IGF2BP3. Genetic Testing and Molecular Biomarkers. https://doi.org/10.1089/gtmb.2023.0531

Vancouver

Gong S, Liu H, Gou H, Sun W. METTL5: A Potential Biomarker for Nonsmall Cell Lung Cancer That Promotes Cancer Cell Proliferation by Interacting with IGF2BP3. Genetic Testing and Molecular Biomarkers. 2024. doi:10.1089/gtmb.2023.0531

BibTeX
@article{Gong2024,
  author = {Gong, Sihan and Liu, Hu and Gou, Hao and Sun, Wanli},
  title = {METTL5: A Potential Biomarker for Nonsmall Cell Lung Cancer That Promotes Cancer Cell Proliferation by Interacting with IGF2BP3},
  journal = {Genetic Testing and Molecular Biomarkers},
  year = {2024},
  doi = {10.1089/gtmb.2023.0531}
}
Kostenlos starten →